📢 Calling all EASL Young Investigators with valid membership! Help us improve the EASL CPG Tool by testing it and sharing your experience. Your feedback will help us enhance its usability, functionality, and clinical relevance! How can you contribute? - Explore and test the EASL CPG Tool - Share your experience and suggestions through our feedback survey 📅 Deadline: 8 November 2026 🔗 Access the tool: easl.eu/llm-prototype-testin… Your insights matter! Take this opportunity to contribute to the development of a tool designed to make EASL Clinical Practice Guidelines more accessible and easier to use in daily practice. Thank you for helping us improve EASL's digital resources! #LiverTwitter #LiverX

Join our next EASL DeepDive to explore AI-driven trial design, patient selection, digital twins, and the use of real-world data to strengthen clinical evidence. Discover the opportunities, scientific challenges, and limitations of AI in clinical research. 📅 Wedneday, 4 November, 18:00 CET Register here: easl-eu.zoom.us/webinar/regi…

In this new episode of #TalkLiverToMe, experts discuss the practical use of resmetirom and semaglutide, based on the 2026 EASL–EASD–EASO Guidance. Who should be treated, when should therapy start, and how should response be monitored? Listen on EASL Campus: easlcampus.eu/tltm/episode-1… Also on Spotify: open.spotify.com/episode/4Wt… and Apple Podcasts: podcasts.apple.com/ch/podcas…

🎆Registration and abstract submission are now open for EASL Congress 2027! 🎆 Join the global hepatology community in London, United Kingdom, from 16 to 19 June 2027, for four inspiring days of cutting-edge science, meaningful exchange and new opportunities to connect, collaborate and shape the future of hepatology. Be a part of this unmissable event. 🔎easlcongress.eu 👉Register with early fees by 19 January: easlcongress.eu/registration… 👉Submit your abstract by 25 January: easlcongress.eu/abstracts/ 📽️youtu.be/v64-u-qcsug?si=kLJ0…

Meet A-TANGO at #EASLCongress 2026! Representatives Cornelius Engelmann and @RajivJalan1 will be discussing the A-TANGO Score: A Novel Tool for Risk Stratification and Clinical Endpoints in ACLF, and answer all your questions! 📅 Friday, 29 May 10:00-10:30 📍Track Hub 6 Register to EASL Congress: easlcongress.eu/2026-registr… #LiverTwitter #LiverX

New Talk Liver to Me episode out now! From xenotransplantation to machine perfusion, liver transplantation is being redefined. What’s the hype? What’s the evidence? What’s ready for practice? Out now on Spotify, Amazon Podcast, and EASL Campus! easlcampus.eu/tltm/episode-0… podcasts.apple.com/us/podcas… open.spotify.com/episode/1od… @Drfattyliver #LiverTwitter #LiverX

🚨 NEW: Nearly 780 people die every day in Europe from liver disease — a largely preventable crisis. The new EASL–Lancet Commission calls for urgent policy action on alcohol, diet, viral hepatitis & more. 👉Full report: thelancet.com/commissions-do…

“For patients living with liver disease, this report is long overdue. Too many people across Europe are still being diagnosed too late, when treatment options are limited and outcomes are poor. The Commission’s recommendations, on earlier detection, integrated care, and tackling the root causes of disease, reflect what patients and their families have been asking for. We now urge policymakers to move from words to action, because for the people we represent, time is not a luxury.” @Marko_Korenjak , President, European Liver Patients Association (ELPA) 🔗 thelancet.com/commissions-do… 📍 Launch of the EASL–Lancet Commission, today in Brussels and online

Register for the next EASL DeepDive to explore key updates in the EASL Guidelines on extrahepatic cholangiocarcinoma (eCCA). Learn how to define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgical management of eCCA. Wednesday, 22 April, 18:00 CEST 🔗 easl-eu.zoom.us/webinar/regi… #LiverTwitter #LiverX

Liver disease is a growing public health challenge across Europe, but evidence can drive real change. Join us for the launch of the EASL–Lancet Commission 2.0 “From Evidence to Impact: Implementing Sustainable Liver Health in Europe.” This event will bring together policymakers, clinicians, researchers, economists and civil society to discuss how the latest evidence and policy recommendations can strengthen prevention, improve early detection and advance liver care across Europe. 📅 30 April 2026 🕒 11:00–13:00 📍 TownHall Europe, Brussels 💻 Online participation available The programme will feature keynote insights from global health leaders and presentations from Commission experts, followed by a panel discussion on translating recommendations into action at EU and national levels. 👉 See the full programme here: lnkd.in/e2srgGiF 👉 Register now: lnkd.in/e6Nx6M-V

EASL is deeply saddened by the loss of Dr Ahmed Elsharkawy, consultant transplant hepatologist, researcher, educator and valued member of the EASL Governing Board. Ahmed served EASL with honesty, courage and a deep commitment to the community he cared so much about. He was never afraid to speak up when it mattered, always guided by a strong sense of fairness and integrity. His leadership helped shape important initiatives that will continue to benefit the liver community for years to come. Beyond his professional achievements, Ahmed will be remembered for his warmth, humour and generosity as a colleague and friend. Our thoughts are with his wife Sarah, his children, his family and all those who knew and worked with him. @DebbieShawcros1 @analleo

🗞️News from A-TANGO! We celebrate a new consortium publication by Cornelius Engelmann et al. (2026) that introduces the A-TANGO organ failure (OF) score, a refined tool for diagnosing acute-on-chronic liver failure (ACLF) in patients with cirrhosis and acute decompensation. Developed using data from 3,896 patients in Europe and Latin America and validated in large cohorts from India and China, the score updates thresholds for organ dysfunction and adds a new ACLF grade 4 to better capture severely ill patients. Compared with the widely used CLIF-C OF score, A-TANGO improves detection of ACLF (24% to 36%) while maintaining strong prediction of 28- and 90-day mortality. The study also introduces two related prognostic models. Together, these tools provide a more accurate framework for risk stratification, treatment evaluation, and the design of clinical trials in ACLF. 👉Read the publication here: sciencedirect.com/science/ar…